U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H14N2O3.C6H14N2O2.2H2O
Molecular Weight 464.5121
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BENDAZAC LYSINE DIHYDRATE

SMILES

O.O.NCCCC[C@H](N)C(O)=O.OC(=O)COC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3

InChI

InChIKey=PSIKNBYUZWDTBM-QEJHLSQBSA-N
InChI=1S/C16H14N2O3.C6H14N2O2.2H2O/c19-15(20)11-21-16-13-8-4-5-9-14(13)18(17-16)10-12-6-2-1-3-7-12;7-4-2-1-3-5(8)6(9)10;;/h1-9H,10-11H2,(H,19,20);5H,1-4,7-8H2,(H,9,10);2*1H2/t;5-;;/m.0../s1

HIDE SMILES / InChI
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C16H14N2O3
Molecular Weight 282.294
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C6H14N2O2
Molecular Weight 146.1876
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://database.japic.or.jp/pdf/newPINS/00056628.pdf http://www.kegg.jp/medicus-bin/japic_med?japic_code=00056628 http://www.ncbi.nlm.nih.gov/pubmed/5317253

Bendazac, (1-benzyl-1H-indazol-3-yl-oxy)-acetic acid, is structurally related to indomethacin. Its lysine salt has been reported to be absorbed better than the parent compound. It is applied topically as bendazac lysine 0.5% (wt/vol) aqueous solution for delaying the progression of cataract. Topical application of bendazac is associated with transient burning sensation. It reduces the secretion of the skin ulcer surface, promotes skin formation and accelerates tissue repair.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
reactive oxygen species
8
Target ID: reactive oxygen species
Modulator
828
Inhibitor
8297
 0.33 mM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Zildasac Ointment

Approved Use

Indications: Pressure sores, burns ulcers, radiation ulcers; Contact dermatitis, acute eczema, atopic dermatitis, chronic eczema, psoriasis vulgaris, infant eczema, herpes zoster
Primary
Approved
8429
Zildasac Ointment

Approved Use

Indications: Pressure sores, burns ulcers, radiation ulcers; Cntact dermatitis, acute eczema, atopic dermatitis, chronic eczema, psoriasis vulgaris, infant eczema, herpes zoster
Primary
Approved
8429
Zildasac Ointment

Approved Use

Indications: Pressure sores, burns ulcers, radiation ulcers; Cntact dermatitis, acute eczema, atopic dermatitis, chronic eczema, psoriasis vulgaris, infant eczema, herpes zoster
Primary
Approved
8429
Zildasac Ointment

Approved Use

Indications: Pressure sores, burns ulcers, radiation ulcers; Cntact dermatitis, acute eczema, atopic dermatitis, chronic eczema, psoriasis vulgaris, infant eczema, herpes zoster
Palliative
Approved
8429
Zildasac Ointment

Approved Use

Indications: Pressure sores, burns ulcers, radiation ulcers; Cntact dermatitis, acute eczema, atopic dermatitis, chronic eczema, psoriasis vulgaris, infant eczema, herpes zoster
Primary
Approved
8429
BENDAZAC LYSINE

Approved Use

Adjuvant in the treatment of cataracts (cataract degenerative presenile and senile, juvenile cataracts, diabetic cataract, opacification of the cortex or the crystalline core of different origin and nature)
PubMed

PubMed

TitleDatePubMed
Gene expression profiling in rat liver treated with compounds inducing elevation of bilirubin.
2009 Apr
Synthesis and biological evaluations of novel bendazac lysine analogues as potent anticataract agents.
2010 Apr 1
Patents

Patents

JP2002541233A
400
JPS62263122A
4

Sample Use Guides

In Vivo Use Guide
Curator's Comment: http://www.chinaphar.com/1671-4083/18/109.pdf http://rbsapp.net:8080/rcap/
Single Dose Eye drops: 2 drops in each eye or half the contents of a single-dose, three times a day Multi-dose eye drops: 2 drops in each eye, three times a day oral: single dosage benzadac lysine in tables (500 mg) Skin ulcers: An appropriate amount of this product is applied to the affected area several times a day. Incidentally, it performs patch therapy 1-2 times daily as needed. Inflammatory skin disease: An appropriate amount of this product is applied to the affected area several times a day.
Route of Administration: Other
In Vitro Use Guide
The inhibition of labelled cyanate binding to lens proteins increased with increasing concentration of bendazac (max at 40 mM).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:15:26 GMT 2023
Edited
by admin
on Fri Dec 15 15:15:26 GMT 2023
Record UNII
MOQ12WCD7V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BENDAZAC LYSINE DIHYDRATE
Common Name English
2-((1-(PHENYLMETHYL)-1H-INDAZOL-3-YL)OXY)ACETIC ACID, L-LYSINE SALT DIHYDRATE
Common Name English
Code System Code Type Description
PUBCHEM
70401396
Created by admin on Fri Dec 15 15:15:26 GMT 2023 , Edited by admin on Fri Dec 15 15:15:26 GMT 2023
PRIMARY
SMS_ID
300000029337
Created by admin on Fri Dec 15 15:15:26 GMT 2023 , Edited by admin on Fri Dec 15 15:15:26 GMT 2023
PRIMARY
FDA UNII
MOQ12WCD7V
Created by admin on Fri Dec 15 15:15:26 GMT 2023 , Edited by admin on Fri Dec 15 15:15:26 GMT 2023
PRIMARY
Related Record Type Details
Structure of LYSINE
PARENT -> SALT/SOLVATE
Structure of BENDAZAC LYSINE
ANHYDROUS->SOLVATE
Structure of BENDAZAC
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of BENDAZAC
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966